British Business Bank takes GBP 8 million equity stake in NRG Therapeutics Series B round

Mechanism

The British Business Bank, wholly owned by the UK government, co-invested alongside private venture funds in a single portfolio company's Series B equity round rather than issuing a loan or grant — the same state development-bank equity-participation model seen elsewhere in the Western industrial-policy stack (e.g. UK National Wealth Fund's Cornish Lithium and Morse Micro stakes). The GBP 8 million stake is a minority position within the GBP 50 million round; the Bank's involvement is explicitly framed as supporting UK life-sciences venture capital depth rather than de-risking a specific supply chain.

Rationale

NRG's lead candidate, NRG5051, had completed IND-enabling studies and was on track for first-in-human clinical trials in early 2026 at the time of the round, targeting clinical proof-of-concept in ALS/MND and clinical data in Parkinson's. The investment sits within the British Business Bank's broader mandate to backstop UK venture funding for scale-up-stage life-sciences companies, a sector the UK has separately flagged as strategically important (see the UK Life Sciences TRIF pilot, filed 2025-09-25, in the same theme).